AC Immune (ACIU) Non Operating Income (2015 - 2026)
AC Immune (ACIU) reported Non Operating Income of -$16601.1 for Q1 2026, down 104.38% year-over-year from $379277.4 in Q1 2025, and down 100.68% on a QoQ basis from $2.4 million in Q4 2025.
AC Immune (ACIU) has 12 years of Non Operating Income data on file, last reported at -$16601.1 in Q1 2026.
- Quarterly Non Operating Income fell 104.38% year-over-year to -$16601.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $636557.0 (up 113.24% YoY) and the FY2025 annual result came in at $968521.2, down 42.09% from the prior year.
- Non Operating Income eased to -$16601.1 in Q1 2026 per ACIU's latest filing, from $2.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.5 million in Q1 2024 and bottomed at -$2.2 million in Q2 2025.
- The 5-year median for Non Operating Income is $65950.9 (2023), against an average of $34993.8.
- Peak annual rise in Non Operating Income reached 3732.21% in 2024, while the deepest fall reached 928.09% in 2024.
- Tracing ACIU's Non Operating Income over 5 years: stood at -$51901.1 in 2022, then jumped by 2904.21% to $1.5 million in 2023, then tumbled by 179.77% to -$1.2 million in 2024, then jumped by 310.48% to $2.4 million in 2025, then sank by 100.68% to -$16601.1 in 2026.
- Per Business Quant, the three latest ACIU Non Operating Income figures stand at -$16601.1 (Q1 2026), $2.4 million (Q4 2025), and $385033.7 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | -16,601.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,601.06 |
| Dec 31, 2025 | 2.44 Mn |
| Sep 30, 2025 | 385,033.73 |
| Jun 30, 2025 | -2.18 Mn |
| Mar 31, 2025 | 379,277.43 |
| Dec 31, 2024 | -2.77 Mn |
| Sep 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -1.99 Mn |
| Mar 31, 2024 | 2.53 Mn |
| Dec 31, 2023 | -259,291.53 |
| Sep 30, 2023 | 369,081.74 |
| Jun 30, 2023 | 240,229.92 |
| Mar 31, 2023 | 65,950.92 |
| Dec 31, 2022 | -51,901.10 |
| Sep 30, 2022 | -50,737.38 |
| Jun 30, 2022 | 227,386.17 |
| Mar 31, 2022 | -15,159.32 |
| Dec 31, 2021 | 1.64 Mn |
| Sep 30, 2021 | 4.75 Mn |
| Jun 30, 2021 | -416,725.90 |
| Mar 31, 2021 | -705,665.68 |
| Dec 31, 2020 | -1.17 Mn |
| Sep 30, 2020 | -205,323.08 |
| Jun 30, 2020 | -52,928.41 |
| Mar 31, 2020 | -400,098.63 |
| Dec 31, 2019 | 423,350.74 |
| Sep 30, 2019 | 239,528.52 |
| Jun 30, 2019 | -2.12 Mn |
| Mar 31, 2019 | 80,325.00 |
| Dec 31, 2018 | -2.63 Mn |
| Sep 30, 2018 | -1.37 Mn |
| Jun 30, 2018 | 433,812.77 |
| Mar 31, 2018 | 307,886.59 |
| Dec 31, 2017 | -4.84 Bn |
| Sep 30, 2017 | 4.96 Bn |
| Jun 30, 2017 | 4.06 Mn |
| Mar 31, 2017 | 1.61 Mn |
| Dec 31, 2016 | 2.43 Mn |
| Sep 30, 2016 | -1.05 Mn |
| Jun 30, 2016 | -494,706.30 |
| Mar 31, 2016 | 393,704.83 |
| Dec 31, 2015 | 2.60 Mn |
| Sep 30, 2015 | 800,211.42 |